Abstract

The hepatitis C virus (HCV) is a primarily hepatotropic virus. However, numerous extrahepatic symptoms are observed in patients chronically infected with HCV, e.g. cryoglobulinemia, lymphoproliferative disorders, kidney diseases, disturbances of the central and peripheral nervous system, thyroid gland, pancreas, lymph nodes and pituitary gland, that develop at various times after the infection. Complex mechanisms underlie these processes, both molecular, related to direct effects of the virus on cells or tissues and indirect mechanisms, resulting from the response of the immune system to infection (via cytokines or oxidative stress), and from the antiviral treatment used. Understanding these mechanisms may contribute to the definition of new prognostic factors, important for the early diagnosis of the infection, which in turn may improve treatment efficacy.This paper is a review of the incidence of selected extrahepatic manifestations of HCV infection and their underlying pathogenetic mechanisms and risk factors.

References

• 1. Adair D.M., Radkowski M., Jablonska J., Pawelczyk A., Wilkinson J.,Rakela J., Laskus T.: Differential display analysis of gene expression inbrains from hepatitis C-infected patients. AIDS, 2005; 19: S145-S150
  Google Scholar
• 2. Adinolfi L.E, Restivo L., Zampino R., Guerrera B., Lonardo A., RuggieroL., Riello F., Loria P., Florio A.: Chronic HCV infection is a riskof atherosclerosis. Role of HCV and HCV related steatosis. Atherosclerosis,2012; 221: 496-502
  Google Scholar
• 3. Ahboucha S., Talani G., Fanutza T., Sanna E., Biggio G., GamraniH., Butterworth R.F.: Reduced brain levels of DHEAS in hepatic comapatients: significance for increased GABAergic tone in hepatic encephalopathy.Neurochem. Int., 2012; 61: 48-53
  Google Scholar
• 4. Akeno N., Blackard J.T., Tomer Y.: HCV E2 protein binds directly tothyroid cells and induces IL-8 production: a new mechanism for HCVinduced thyroid autoimmunity. J. Autoimmun., 2008; 31: 339-344
  Google Scholar
• 5. Altraif I.H., Abdulla A.S., al Sebayel M.I., Said R.A., al SuhaibaniM.O., Jones A.A.: Hepatitis C associated glomerulonephritis. Am. J.Nephrol., 1995; 15: 407-410
  Google Scholar
• 6. Andrade L.J., Atta A.M., Atta M.L., Mangabeira C.N., Paraná R.:Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy. Braz. J. Infect. Dis., 2011: 15: 377-381
  Google Scholar
• 7. Arase Y., Ikeda K., Murashima N., Chayama K., Tsubota A., KoidaI., Suzuki Y., Saitoh S., Kobayashi M., Kobayashi M., Kobayashi M.,Kumada H.: Glomerulonephritis in autopsy cases with hepatitis Cvirus infection. Intern. Med., 1998: 37: 836-840
  Google Scholar
• 8. Benvegnù L., Gios M., Boccato S., Alberti A.: Natural history ofcompensated viral cirrhosis: a prospective study on the incidenceand hierarchy of major complications. Gut, 2004, 53: 744-749 9 Blackard J.T., Kong L., Huber A.K., Tomer Y.: Hepatitis C virusinfection of a thyroid cell line: implications for pathogenesis of hepatitisC virus and thyroiditis. Thyroid, 2013; 23: 863-870
  Google Scholar
• 9. expression is associated with progressive liver diseasein chronic hepatitis C virus infection: role of viral core and NS5Aproteins. Gut, 2004; 53: 1665-1672
  Google Scholar
• 10. Bokemeyer M., Ding X.Q., Goldbecker A., Raab P., Heeren M.,Arvanitis D., Tillmann H.L., Lanfermann H., Weissenborn K.: Evidencefor neuroinflammation and neuroprotection in HCV infection-associatedencephalopathy. Gut, 2011; 60: 370-377
  Google Scholar
• 11. Borg F.A., Isenberg D.A.: Syndromes and complications of interferontherapy. Curr. Opin. Rheumatol., 2007; 19: 61-66
  Google Scholar
• 12. Brost S., Zimmermann A., Koschny R., Sykora J., Stremmel W.,Schirmacher P., Walczak H., Ganten T.M.: Hepatocyte expression ofTRAIL pathway regulators correlates with histopathological andclinical parameters in chronic HCV infection. Pathol. Res. Pract.,2014; 210: 83-91
  Google Scholar
• 13. Burdette D., Haskett A., Presser L., McRae S., Iqbal J., Waris G.:Hepatitis C virus activates interleukin-1β via caspase-1-inflammasomecomplex. J. Gen. Virol., 2012; 93: 235-246
  Google Scholar
• 14. Butt A.A., Xiaoqiang W., Budoff M., Leaf D., Kuller L.H., JusticeA.C.: Hepatitis C virus infection and the risk of coronary disease.Clin. Infect. Dis., 2009; 49: 225-232
  Google Scholar
• 15. Cappellari A., Origgi L., Spina M.F., Yiannopoulou K.G., Meola G.,Vanoli M., Ciammola A., Gregorini F., Scorza R., Bresolin N.: Centralnervous system involvement in HCV-related mixed cryoglobulinemia.Electromyogr. Clin. Neurophysiol., 2006; 46: 149-158
  Google Scholar
• 16. Cappola A.R., Fried L.P., Arnold A.M., Danese M.D., Kuller L.H.,Burke G.L., Tracy R.P., Ladenson P.W.: Thyroid status, cardiovascularrisk, and mortality in older adults. JAMA, 2006; 295: 1033-1041
  Google Scholar
• 17. Cavalli G., Berti A., Fragasso G., De Cobelli F.: Hypertrophic cardiomyopathysecondary to hepatitis C virus-related vasculitis. J.Cardiovasc. Med., 2014 (w druku)
  Google Scholar
• 18. Cheng Z., Zhou B., Shi X., Zhang Y., Zhang L., Chen L., Liu X.:Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin. Med.J., 2014; 127: 1206-1210
  Google Scholar
• 19. Ciufu C., Arama V., Bumbea H., Dobrea C., Ion I., VladareanuA.M.: Correlations of hematological parameters with bone marrowfindings in chronic lymphoproliferative disorders associated withhepatitis viruses. J. Med. Life, 2013; 6: 464-471
  Google Scholar
• 20. Daniel A.L., Houlihan J.L, Blum J.S., Walsh J.P.: Type B insulinresistance developing during interferon-α therapy. Endocr. Pract.,2009; 15: 153-157
  Google Scholar
• 21. Dávalos Moscol M., Bustios Sanchez C.: The burden of hepaticencephalopathy in Latin America. Ann. Hepatol., 2011; 10: S31-S35
  Google Scholar
• 22. De Franceschi L., Fattovich G., Turrini F., Ayi K., Brugnara C.,Manzato F., Noventa F., Stanzial A.M., Solero P., Corrocher R.: Hemolyticanemia induced by ribavirin therapy in patients with chronichepatitis C virus infection: role of membrane oxidative damage.Hapatology, 2000; 31: 997-1004
  Google Scholar
• 23. Dietrich C.F., Lee J.H., Herrmann G., Teuber G., Roth W.K., CasparyW.F., Zeuzem S.: Enlargement of perihepatic lymph nodes in relationto liver histology and viremia in patients with chronic hepatitis C.Hepatology, 1997; 26: 467-472
  Google Scholar
• 24. Dietrich C.F., Stryjek-Kaminska D., Teuber G., Lee J.H., CasparyW.F., Zeuzem S.: Perihepatic lymph nodes as a marker of antiviralresponse in patients with chronic hepatitis C infection. Am. J. Roentgenol.,2000; 174: 699-704
  Google Scholar
• 25. Fattovich G., Pantalena MZagni I., Realdi G., Schalm S.W., ChristensenE.: Effect of hepatitis B and C virus infections on the naturalhistory of compensated cirrhosis: a cohort study of 297 patients. Am.J. Gastroenterol., 2002; 97: 2886-2895
  Google Scholar
• 26. Ferreira C.N., Barjas E.R., Correia L.A., Tavares L., Ferreira C.,Serejo F.L., de Moura M.C., Monteiro E.: Generalized peripheral lymphadenopathy in a patient treated for chronic HCV infection.Nat. Clin. Pract. Gastroenterol. Hepatol., 2008; 5: 469-474
  Google Scholar
• 27. Fletcher N.F., Wilson G.K., Murray J., Hu K., Lewis A., ReynoldsG.M., Stamataki Z., Meredith L.W., Rowe I.A., Luo G., Lopez-RamirezM.A., Baumert T.F., Weksler B., Couraud P.O., Kim K.S., Romero I.A.,Jopling C., Morgello S., Balfe P., McKeating JA.: Hepatitis C virus infectsthe endothelial cells of the blood-brain barrier. Gastroenterology,2012; 142: 634-643
  Google Scholar
• 28. Fletcher N.F., Yang J.P., Farquhar M.J., Hu K., Davis C., He Q., DowdK., Ray S.C., Krieger S.E., Neyts J., Baumert T.F., Balfe P., McKeatingJ.A., Wong-Staal F.: Hepatitis C virus infection of neuroepitheliomacell lines. Gastroenterology, 2010; 139: 1365-1374
  Google Scholar
• 29. Forton D.M., Hamilton G., Allsop J.M., Grover V.P., Wesnes K.,O’Sullivan C., Thomas H.C., Taylor-Robinson S.D.: Cerebral immuneactivation in chronic hepatitis C infection: a magnetic resonancespectroscopy study. J. Hepatol., 2008; 49: 316-322
  Google Scholar
• 30. Forton D.M., Thomas H.C., Murphy C.A., Allsop J.M., Foster G.R.,Main J., Wesnes K.A., Taylor-Robinson S.D.: Hepatitis C and cognitiveimpairment in a cohort of patients with mild liver disease. Hepatology,2002; 35: 433-439
  Google Scholar
• 31. Franch-Arcas G.: The meaning of hypoalbuminaemia in clinicalpractice. Clin. Nutr., 2001; 20: 265-269
  Google Scholar
• 32. Gess M., Forton D.: Peripheral markers of immune activationare not associated with depression and cognitive impairment beforeand during antiviral therapy in chronic hepatitis C infection.Gut, 2010; 59: A46
  Google Scholar
• 33. Goh J., Coughlan B., Quinn J., O’Keane J.C., Crowe J.: Fatigue doesnot correlate with the degree of hepatitis or the presence of autoimmunedisorders in chronic hepatitis C infection. Eur. J. Gastroenterol.Hepatol., 1999; 11: 833-838
  Google Scholar
• 34. Goutagny N., Fatmi A., De Ledinghen V., Penin F., Couzigou P.,Inchauspé G., Bain C.: Evidence of viral replication in circulatingdendritic cells during hepatitis C virus infection. J. Infect. Dis., 2003;187: 1951-1958
  Google Scholar
• 35. Gursoy S., Baskol M., Ozbakir O., Guven K., Kelestimur F., YucesoyM.: Hypothalamo-pituitary gonadal axis in men with chronic hepatitis.Hepatogastroenterology, 2004; 51: 787-790
  Google Scholar
• 36. Hikita H., Nakagawa H., Tateishi R., Masuzaki R., Enooku K.,Yoshida H., Omata M., Soroida Y., Sato M., Gotoh H., Suzuki A., IwaiT., Yokota H., Koike K., Yatomi Y., Ikeda H.: Perihepatic lymph nodeenlargement is a negative predictor of liver cancer developmentin chronic hepatitis C patients. J. Gastroenterol., 2013; 48: 366-373
  Google Scholar
• 37. Hilsabeck R.C., Perry W., Hassanein T.I.: Neuropsychologicalimpairment in patients with chronic hepatitis C. Hepatology, 2002;35: 440-446
  Google Scholar
• 38. Horikoshi S., Okada T., Shirato I., Inokuchi S., Ohmuro H., TominoY., Koide H.: Diffuse proliferative glomerulonephritis with hepatitisC virus-like particles in paramesangial dense deposits in a patientwith chronic hepatitis C virus hepatitis. Nephron, 1993: 64: 462-464
  Google Scholar
• 39. Huang J.F., Chuang W.L., Dai C.Y., Chen S.C., Lin Z.Y., Lee L.P., LeeP.L., Wang L.Y., Hsieh M.Y., Chang WY, Yu M.L.: The role of thyroidautoantibodies in the development of thyroid dysfunction in Taiwanesechronic hepatitis C patients with interferon-α and ribavirincombination therapy. J. Viral Hepat., 2006; 13: 396-401
  Google Scholar
• 40. Idilman R., Colantoni A., De Maria N., Alkan S., Nand S., VanThiel D.: Lymphoproliferative disorders in chronic hepatitis C. J.Viral Hepat., 2004; 11: 302-309
  Google Scholar
• 41. Ishizaka N., Ishizaka Y., Takahashi E., Tooda E.I., Hashimoto H.,Nagai R., Yamakado M.: Association between hepatitis C virus seropositivity,carotid-artery plaque, and intima-media thickening.Lancet, 2002; 359: 133-135
  Google Scholar
• 42. Ishizaka Y., Ishizaka N., Takahashi E., Unuma T., Tooda E., HashimotoH., Nagai R., Yamakado M.: Association between hepatitis C virus core protein and carotid atherosclerosis. Circ. J., 2003; 67: 26-30
  Google Scholar
• 43. Johnson R.J., Gretch D.R., Yamabe H., Hart J., Bacchi C.E., HartwellP., Couser W.G., Corey L., Wener M.H., Alpers C.E.: Membranoproliferativeglomerulonephritis associated with hepatitis C virusinfection. N. Engl. J. Med., 1993; 328: 465-470
  Google Scholar
• 44. Jung H.J., Kim Y.S., Kim S.G., Lee Y.N., Jeong S.W., Jang J.Y., LeeS.H., Kim H.S., Kim B.S.: The impact of pegylated interferon andribavirin combination treatment on lipid metabolism and insulinresistance in chronic hepatitis C patients. Clin. Mol. Hepatol., 2014;20: 38-46
  Google Scholar
• 45. Kawaguchi T., Ide T., Taniguchi E., Hirano E., Itou M., Sumie S.,Nagao Y., Yanagimoto C., Hanada S., Koga H., Sata M.: Clearance ofHCV improves insulin resistance, beta-cell function, and hepaticexpression of insulin receptor substrate 1 and 2. Am. J. Gastroenterol.,2007; 102: 570-576
  Google Scholar
• 46. Kim T.H., Um S.H., Yim S.Y., Seo Y.S., Yim H.J., Jeen Y.T., Lee H.S.,Chun H.J., Kim C.D., Ahn H., Lee Y.: The risk of perioperative adverseevents in patients with chronic liver disease. Liver Int., 2014; 3: 1-11
  Google Scholar
• 47. Kisiel E., Radkowski M., Pawelczyk A., Horban A., Stanczak J.,Bukowska-Ośko I., Caraballo Cortes K., Kaźmierczak J., Popiel M.,Laskus T.: Seronegative hepatitis C virus infection in patients withlymphoproliferative disorders. J. Viral Hepat., 2014; 21: 424-429
  Google Scholar
• 48. Klco J.M., Geng B., Brunt E.M., Hassan A., Nguyen T.D., KreiselF.H., Lisker-Melman M., Frater J.L.: Bone marrow biopsy in patientswith hepatitis C virus infection: spectrum of findings and diagnosticutility. Am. J. Hematol., 2010; 85: 106-110
  Google Scholar
• 49. Koh L.K., Greenspan F.S., Yeo P.P.: Interferon-α induced thyroiddysfunction: three clinical presentations and a review of the literature.Thyroid, 1997; 7: 891-896
  Google Scholar
• 50. Lake-Bakaar G., Jacobson I., Talal A.: B cell activating factor(BAFF) in the natural history of chronic hepatitis C virus liver diseaseand mixed cryoglobulinaemia. Clin. Exp. Immunol., 2012; 170:231-237
  Google Scholar
• 51. Lerat H., Berby F., Trabaud M.A., Vidalin O., Major M., Trépo C.,Inchauspé G.: Specific detection of hepatitis C virus minus strandRNA in hematopoietic cells. J. Clin. Invest., 1996; 97: 845-851
  Google Scholar
• 52. Lerat H., Rumin S., Habersetzer F., Berby F., Trabaud M.A., TrépoC., Inchauspé G.: In vivo tropism of hepatitis C virus genomic sequencesin hematopoietic cells: influence of viral load, viral genotype,and cell phenotype. Blood, 1998; 91: 3841-3849
  Google Scholar
• 53. Liao C.C., Su T.C., Sung F.C., Chou W.H., Chen T.L.: Does hepatitisC virus infection increase risk for stroke? A population-based cohortstudy. PLoS One, 2012; 7: e31527
  Google Scholar
• 54. Liu Z., Zhao F., He J.J.: Hepatitis C virus (HCV) interaction withastrocytes: nonproductive infection and induction of IL-18. J. Neurovirol.,2014; 20: 278-293
  Google Scholar
• 55. Mandac J.C., Chaudhry S., Sherman K.E., Tomer Y.: The clinicaland physiological spectrum of interferon-alpha induced thyroiditis:toward a new classification. Hepatology, 2006; 43: 661-672
  Google Scholar
• 56. Mao X.R., Zhang L.T., Chen H., Xiao P., Zhang Y.C.: Possible factorsaffecting thyroid dysfunction in hepatitis C virus-infected untreatedpatients. Exp. Ther. Med., 2014; 8: 133-140
  Google Scholar
• 57. Markowitz G.S, Cheng J.T, Colvin R.B, Trebbin W.M., D’Agati V.D.:Hepatitis C viral infection is associated with fibrillary glomerulonephritisand immunotactoid glomerulopathy. J. Am. Soc. Nephrol.,1998; 9: 2244-2252
  Google Scholar
• 58. Masini M., Campani D., Boggi U., Menicagli M., Funel N., PolleraM., Lupi R., Del Guerra S., Bugliani M., Torri S., Del Prato S., MoscaF., Filipponi F., Marchetti P.: Hepatitis C virus infection and humanpancreatic β-cell dysfunction. Diabetes Care, 2005; 28: 940-941
  Google Scholar
• 59. Mazzocca A., Sciammetta S.C, Carloni V., Cosmi L., Annuziato F.,Harada T., Abrignani S., Pinzani M.: Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2in human hepatic stellate cells. J. Biol. Chem., 2005; 280: 11329-11339
  Google Scholar
• 60. Mencin A., Kluwe J., Schwabe R.F.: Toll-like receptors as targetsin chronic liver diseases. Gut, 2009; 58: 704-720
  Google Scholar
• 61. Minutolo A., Conti B., Grelli S., Viscomi C., Labbadia G., BalsanoC.: Lymphocytes as liver damage mirror of HCV related adipogenesisderegulation. PLoS One, 2014; 9: 1-10
  Google Scholar
• 62. Misiani R., Bellavita P., Fenili D., Borelli G., Marchesi D., MassazzaM., Vendramin G., Comotti B., Tanzi E., Scudeller G., Zanetti A.:Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.Ann. Intern. Med., 1992; 117: 573-577
  Google Scholar
• 63. Mousa S.M.: Hepatitis C among Egyptian patients referred forbone marrow examination: seroprevalence and analysis of hematologicalfindings. Bone Marrow Res., 2014; 2014: 549716
  Google Scholar
• 64. Naeshiro N., Aikata H., Hyogo H., Kan H., Fujino H., Kobayashi T.,Fukuhara T., Honda Y., Nakahara T., Ohno A., Miyaki D., Murakami E.,Kawaoka T., Tsuge M., Hiraga N., Hiramatsu A., Imamura M., KawakamiY., Ochi H., Chayama K.: Efficacy and safety of the anticoagulantdrug, danaparoid sodium, for the treatment of portal vein thrombosisin patients with liver cirrhosis. Hepatol. Res., 2015; 45: 656-662
  Google Scholar
• 65. Nakamura K., Kawasaki E., Imagawa A., Awata T., Ikegami H.,Uchigata Y., Kobayashi T., Shimada A., Nakanishi K., Makino H., MaruyamaT., Hanafusa T., Research Committee on Type 1 Diabetes ofthe Japan Diabetes Society: Type 1 diabetes and interferon therapy:a nationwide survey in Japan. Diabetes Care, 2011; 34: 2084-2089
  Google Scholar
• 66. Neri S., Ierna D., Mauceri B., Abate G., Cilio D., Bordonaro F.,Calvagno S., Balsamo D., Pulvirenti D., Magliocco O., Ignaccolo L.,Malaguarnera M., Caruso L.: Can ultrasonographic findings of perihepaticlymphadenopathy promote investigations to detect possiblepresence of virus C infection in non-symptomatic subjects? Hepatol.Res., 2003; 27: 124-128
  Google Scholar
• 67. Nishitsuji H., Funami K., Shimizu Y., Ujino S., Sugiyama K., SeyaT., Takaku H., Shimotohno K.: Hepatitis C virus infection inducesinflammatory cytokines and chemokines mediated by the cross talkbetween hepatocytes and stellate cells. J. Virol., 2013; 87: 8169-8178
  Google Scholar
• 68. Northup P.G.: Hypercoagulation in liver disease. Clin. Liver Dis.,2009; 13: 109-116
  Google Scholar
• 69. Núñez O., Fernández-Martínez A., Majano P.L., Apolinario A.,Gómez-Gonzalo M., Benedicto I., López-Cabrera M., Boscá L., ClementeG., García-Monzón C., Martín-Sanz P.: Increased intrahepaticcyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase
  Google Scholar
• 70. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., LemonS.M., Weinman S.A.: Mitochondrial injury, oxidative stress, and antioxidantgene expression are induced by hepatitis C virus coreprotein. Gastroenterology, 2002; 122: 366-375
  Google Scholar
• 71. Oliveira A.L., de Paula M.N., Comar J.F., Vilela V.R., Peralta R.M.,Bracht A.: Adrenergic metabolic and hemodynamic effects of octopaminein the liver. Int. J. Mol. Sci., 2013; 14: 21858-21872
  Google Scholar
• 72. Oliveira C.P., Kappel C.R., Siqueira E.R., Lima V.M., Stefano J.T.,Michalczuk M.T., Marini S.S., Barbeiro H.V., Soriano F.G., CarrilhoF.J., Pereira L.M., Alvares-da-Silva M.R.: Effects of hepatitis C viruson cardiovascular risk in infected patients: a comparative study. Int.J. Cardiol., 2013; 164: 221-226
  Google Scholar
• 73. Oren R., Brill S., Halpern Z.: Liver function in cirrhotic patientsin the euthyroid versus the hypothyroid state. J. Clin. Gastroenterol.,1998; 27: 339-341
  Google Scholar
• 74. Pal S., Sullivan D.G., Kim S., Lai K.K., Kae J., Cotler S.J., CarithersR.L. Jr, Wood B.L., Perkins J.D., Gretch D.R.: Productive replication ofhepatitis C virus in perihepatic lymph nodes in vivo: implications ofHCV lymphotropism. Gastroenterology, 2006; 130: 1107-1116
  Google Scholar
• 75. Paprocka J., Jamroz E.: Hyperammonemia in children: on thecrossroad of different disorders. Neurologist, 2012; 18: 261-265
  Google Scholar
• 76. Peck-Radosavljevic M., Wichlas M., Homoncik-Kraml M., KreilA., Hofer H., Jessner W., Gangl A., Ferenci P.: Rapid suppression ofhematopoiesis by standard or pegylated interferon-α. Gastroenterology,2002; 123: 141-151
  Google Scholar
• 77. Pham T.N., MacParland S.A., Mulrooney P.M., Cooksley H., NaoumovN.V, Michalak T.I.: Hepatitis C virus persistence after spontaneous ortreatment-induced resolution of hepatitis C. J. Virol., 2004; 78: 5867-5874
  Google Scholar
• 78. Popescu C., Popescu G.A., Arama V.: Type 1 diabetes mellituswith dual autoimmune mechanism related to pegylated interferonand ribavirin treatment for chronic HCV Hepatitis. J Gastrointestin.Liver Dis., 2013; 22: 101-104
  Google Scholar
• 79. Prummel M.F., Laurberg P.: Interferon-α and autoimmune thyroiddisease. Thyroid, 2003; 13: 547-551
  Google Scholar
• 80. Ridruejo E., Christensen A.F., Mando O.G.: Central hypothyroidismand hypophysitis during treatment of chronic hepatitis C withpegylated interferon α and ribavirin. Eur. J. Gastroenterol. Hepatol.,2006; 18: 693-694
  Google Scholar
• 81. Saito T., Owen D.M., Jiang F., Marcotrigiano J., Gale M.Jr.: Innateimmunity induced by composition-dependent RIG-I recognition ofhepatitis C virus RNA. Nature, 2008; 454: 523-527
  Google Scholar
• 82. Sanchez M.J., Bergasa N.V.: Hepatitis C associated cardiomyopathy:potential pathogenic mechanisms and clinical implications.Med. Sci. Monit., 2008; 14: RA55-RA63
  Google Scholar
• 83. Sangiovanni A., Del Ninno E., Fasani P., De Fazio C., Ronchi G.,Romeo R., Morabito A., de Franchis R., Colombo M.: Increased survivalof cirrhotic patients with a hepatocellular carcinoma detectedduring surveillance. Gastroenterology, 2004; 126: 1005-1014
  Google Scholar
• 84. Sanjose S., Benavente Y., Vajdic C.M., Engels E.A., Morton L.M.,Bracci P.M., Spinelli J.J., Zheng T., Zhang Y., Franceschi S., TalaminiR., Holly E.A., Grulich A.E., Cerhan J.R., Hartge P. i wsp.: Hepatitis Cand non-Hodgkin lymphoma among 4784 cases and 6269 controlsfrom the International Lymphoma Epidemiology Consortium. Clin.Gastroenterol. Hepatol., 2008; 6: 451-458
  Google Scholar
• 85. Sansonno D., Lauletta G., Nisi L., Gatti P., Pesola F., Pansini N.,Dammacco F.: Non-enveloped HCV core protein as constitutive antigenof cold-precipitable immune complexes in type II mixed cryoglobulinaemia.Clin. Exp. Immunol., 2003; 133: 275-282
  Google Scholar
• 86. Schreuder T.C., Gelderblom H.C., Weegink C.J., Hamann D., ReesinkH.W., Devries J.H., Hoekstra J.B., Jansen P.L.: High incidenceof type 1 diabetes mellitus during or shortly after treatment withpegylated interferon alpha for chronic hepatitis C virus infection.Liver Int., 2008; 28: 39-46
  Google Scholar
• 87. Soresi M., Bonfissuto G., Sesti R., Riili A., Di Giovanni G., CarroccioA., Tripi S., Montalto G.: Perihepatic lymph nodes and antiviralresponse in chronic HCV-associated hepatitis. Ultrasound Med. Biol.,2004; 30: 711-717
  Google Scholar
• 88. Stehman-Breen C., Alpers C.E., Fleet W.P., Johnson R.J.: Focal segmentalglomerular sclerosis among patients infected with hepatitisC virus. Nephron, 1999; 81: 37-40
  Google Scholar
• 89. Tavakoli-Tabasi S., Ninan S.: Clinical significance of perihepaticlymphadenopathy in patients with chronic hepatitis C infection. Dig.Dis. Sci., 2011; 56: 2137-2144
  Google Scholar
• 90. Tran H.A., Reeves G.E.: The spectrum of autoimmune thyroiddisease in the short to medium term following interferon α therapyfor chronic hepatitis C. Int. J. Endocrinol., 2009; 2009: 241786
  Google Scholar
• 91. Tsutsumi T., Suzuki T., Shimoike T., Suzuki R., Moriya K., ShintaniY., Fujie H., Matsuura Y., Koike K., Miyamura T.: Interaction ofhepatitis C virus core protein with retinoid X receptor α modulatesits transcriptional activity. Hepatology, 2002; 35: 937-946
  Google Scholar
• 92. Vassalle C., Masini S., Bianchi F., Zucchelli G.C.: Evidence forassociation between hepatitis C virus seropositivity and coronaryartery disease. Heart, 2004; 90: 565-566
  Google Scholar
• 93. Völzke H., Schwahn C., Wolff B., Mentel R., Robinson D.M., KleineV., Felix S.B., John U.: Hepatitis B and C virus infection and therisk of atherosclerosis in a general population. Atherosclerosis, 2004;174: 99-103
  Google Scholar
• 94. Wang Q.M., Yin X.Y., Duan Z.J., Guo S.B., Sun X.Y.: Role of theheme oxygenase/carbon monoxide pathway in the pathogenesis andprevention of hepatic encephalopathy. Mol. Med. Rep., 2013; 8: 67-74
  Google Scholar
• 95. Watanabe N., Aizaki H., Matsuura T., Kojima S., Wakita T., SuzukiT.: Hepatitis C virus RNA replication in human stellate cells regulatesgene expression of extracellular matrix-related molecules. Biochem.Biophys. Res. Commun., 2011; 407: 135-140
  Google Scholar
• 96. Wilkinson J., Radkowski M., Eschbacher J.M., Laskus T.: Activationof brain macrophages/microglia cells in hepatitis C infection.Gut, 2010; 59: 1394-1400
  Google Scholar
• 97. Wilkinson J., Radkowski M., Laskus T.: Hepatitis C virus neuroinvasion:identification of infected cells. J. Virol., 2009; 83: 1312-1319
  Google Scholar
• 98. Yamabe H., Johnson R.J., Gretch D.R., Fukushi K., Osawa H., MiyataM., Inuma H., Sasaki T., Kaizuka M., Tamura N.: Hepatitis C virusinfection and membranoproliferative glomerulonephritis in Japan.J. Am. Soc. Nephrol., 1995; 6: 220-223
  Google Scholar
• 99. Yamazaki M., Sato A., Takeda T., Komatsu M.: Distinct clinicalcourses in type 1 diabetes mellitus induced by peg-interferon-αtreatment for chronic hepatitis C. Intern. Med., 2010; 49: 403-407
  Google Scholar
• 100. Yatsuhashi H., Ohnishi Y., Nakayama S., Iwase H., Nakamura T.,Imwari M.: Anti-hypoalbuminemic effect of branched-chain aminoacid granules in patients with liver cirrhosis is independent of dietaryenergy and protein intake. Hepatol. Res., 2011; 41: 1027-1035
  Google Scholar

Full text